“Without Us, There Wouldn’t Be a Tournament”: Why Tennis Needs to Start Treating Players Like the Assets They Are
When Aryna Sabalenka looked into the cameras in Rome and said, “Without us there wouldn’t be a tournament, and there wouldn’t be that entertainment,” she wasn’t just venting. She was stating the most basic—and most ignored—truth in the sports business.
Assets aren’t the stadiums, the logos, or the broadcast trucks.
Assets are the athletes.
And right now, in tennis, the assets are starting to talk about walking. Whether by boycott or injury…both can be devastating.
The money machine behind the Slams
Let’s start with the business backdrop.
The French Open’s 2026 prize pool climbed to about $72.3 million, but that represents only around 15% of the tournament’s projected revenue—down from 15.5% the year before, and well short of the 22% share players are targeting by 2030, in line with joint ATP/WTA 1000 events like Indian Wells and the Italian Open.
Zoom out across the Grand Slams and the commercial picture is even clearer:
Wimbledon alone generated an estimated $124.7 million in sponsorship revenue across 17 deals in 2024, leading all Slams on that front.
Media rights for the four majors are sold into some of the most valuable broadcast portfolios in global sport, with peak domestic audiences in the millions and global reach in the hundreds of markets.
In other words: the Slams are not quaint tennis tournaments. They are global media properties with nine‑figure commercial ecosystems built on three pillars:
Media rights
Sponsorship and hospitality
Ticketing and on‑site spend
All three depend on one thing: the presence of the best players in the world, on court, when the red light on the camera goes on.
Revenue shares: tennis vs the rest of the sports world
Sabalenka, Coco Gauff, and others aren’t just asking for “more money”—they’re asking for a share that reflects the value they create.
Right now:
Players at the French Open are getting ~15% of projected tournament revenue.
By comparison, players in the NFL, NBA, and MLB typically receive close to 50% of league revenue under their collective bargaining agreements.
The WNBA recently moved its player share from roughly 9.3% to about 20% in its 2026 CBA—a major step toward aligning compensation with value.
So when Gauff points out that players ranked 50–200 in the world are effectively living paycheck to paycheck, while the Slams print money, she’s not being dramatic—she’s describing a structural imbalance.
In most major leagues, if the stars walked, the business model would be in immediate crisis. Tennis has somehow convinced itself that the show would go on.
When the asset disappears: boycott vs injury
Here’s where it gets interesting from a business‑risk perspective.
There are two ways a star disappears from your marquee event:
By choice – a boycott, a labor dispute, a coordinated stand like the one Sabalenka is floating.
By chance – injuries, surgeries, chronic overload that finally forces a player to shut it down.
From a balance‑sheet perspective, both scenarios have the same first‑order effect:
the asset is unavailable, and the product degrades.
Fewer marquee matchups.
Lower broadcast ratings.
Reduced sponsor activation value.
Softer ticket demand and hospitality spend.
The difference is controllability.
Injuries are an unfortunate, often unavoidable cost of doing business in elite sport.
Boycotts are a governance failure—a signal that the economic and decision‑making structures around the sport have ignored risk until it became existential.
The injury reality: tennis already lives on a knife’s edge
Professional tennis is already a high‑attrition environment. The calendar is long, surfaces change, travel is relentless, and the physical load is asymmetric and repetitive.
Broadly, research on elite tennis shows:
High rates of overuse injuries (shoulder, elbow, wrist, hip, lower back) driven by repetitive serving and groundstrokes.
Lower‑limb injuries (ankle sprains, knee issues, stress fractures) that can sideline players for weeks to months.
Post‑surgical recovery timelines that often range from 6–12 months for major shoulder, hip, or elbow procedures, with no guarantee of returning to prior ranking or earning power.
Women and men both face significant injury burdens, with some studies suggesting women may experience higher rates of certain overuse injuries, while men may show higher incidence in specific power‑related or acute injuries. The details vary by study, but the pattern is consistent: tennis grinds down its assets.
Every time a top‑10 player undergoes surgery or shuts down a season, the tour quietly absorbs the hit:
A Slam loses a potential box‑office draw.
A broadcaster loses a storyline.
A sponsor loses a face of the campaign.
No one calls it a “boycott,” but the effect on the product can be similar: the best are not there.
The economics of absence
Now layer in the financial reality for players.
At the very top, endorsement deals and appearance fees can cushion the blow of time away. But for the rank‑and‑file:
A long injury layoff can mean months with no prize money, while fixed costs—coaches, physios, travel, housing—keep ticking.
A slide in ranking can mean qualifying instead of main draw, or missing the cut entirely, which cascades into fewer points, less visibility, and reduced sponsor interest.
This is exactly what Gauff was pointing to: the 50–200 band of players who are good enough to be among the best in the world, but not insulated by eight‑figure endorsement portfolios.
When those players are absent due to injury, the ecosystem quietly accepts it as “part of sport.”
When those same players start talking about being absent by choice, suddenly everyone remembers how valuable they are.
Boycott as a mirror
Sabalenka’s suggestion of a potential Grand Slam boycott is not just a threat; it’s a mirror held up to the industry.
Injuries say:
Your calendar, surfaces, and demands are pushing bodies to the edge.
A boycott says:
Your economic model and governance are pushing players to the edge.
Both are signals that the sport is extracting more from its assets than it is reinvesting in them—whether in health, security, or voice.
And the irony is sharp: the same tournaments that can command nine‑figure sponsorship portfolios and premium global media rights are balking at moving player revenue share from the mid‑teens toward the 20s, while other leagues sit near 50%.
If you were valuing tennis like a business
If you looked at tennis the way an investor looks at a company, you’d ask:
Where does the value originate?
From the unique, non‑replicable performance of elite athletes on the biggest stages.What is the key risk?
That those athletes are unavailable—through injury, burnout, or organized withdrawal.What is the mitigation strategy?
Invest in the asset:Fairer revenue sharing and economic security.
Health, recovery, and scheduling reforms that reduce injury risk.
Governance structures that give players a real seat at the table.
Right now, the Slams are effectively under‑insuring their core asset. They’re running a high‑margin business on the assumption that the players will always show up, no matter how the pie is sliced.
Sabalenka’s statement is a reminder that this assumption has an expiry date.
Sources:
Sabalenka, Gauff Suggest Grand Slam Boycott Over Prize Money Share
The Business of the Tennis Grand Slams 2025: Wimbledon Leads ...
https://radlwire.com/business-of-grand-slams-tennis/
Business of the Tennis Grand Slams 2025 – Property Profile, Sponsorship ...
https://www.globaldata.com/store/report/tennis-grand-slams-business-analysis/
